Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:28 PM
Ignite Modification Date:
2025-12-24 @ 6:28 PM
NCT ID:
NCT00802568
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Diagnosis of multiple myeloma, meeting 1 of the following criteria:
* Stage I disease with a bone lesion
* Stage II or III disease meeting any of the following criteria:
* Elevated beta-2 microglobulin
* Deletion of chromosome 13
* Refractory or relapsed disease
* Presence of an evaluable monoclonal component
* Must have achieved reduction of primary tumor after receiving prior intensified chemotherapy with high-dose melphalan and cyclosporine with autologous transplantation
* HLA identical family donor available
* Bone marrow transplantation is allowed in case hematopoietic stem cell collection fails
PATIENT CHARACTERISTICS:
* Karnofsky 70-100%
* No contraindications to allogeneic transplantation
* No contraindications to drugs used in conditioning regimen
* No psychiatric illness
* No other cancer within the past 5 years except basal cell skin cancer or epithelioma in situ of the cervix
* No serious and uncontrolled infection
* Not pregnant or nursing
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* At least 1 month since participation in another prior clinical trial
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT00802568
Study Brief:
Protocol Section:
NCT00802568